

In re Application of: Francesca LEVI-SCHAFFER et al
 Serial No.: 10/594,926
 Filed: April 30, 2008
 Office Action Mailing Date: October 1, 2010

Examiner: ROONEY Nora Maureen
 Group Art Unit: 1644
 Attorney Docket: 32379
 Confirmation No.: 5770

In the Claims:

1-41. (Cancelled)

42. (Currently Amended) A bi-specific antibody comprising:

(i) a₁ first target recognition component which specifically binds to the inhibitory receptor IRp60 ~~or homologues thereof~~; and

(ii) a second target recognition component which specifically binds to a marker specific for a mast cell, an eosinophil and/or a basophil, said marker being selected from the group consisting of IgE, cKIT, CCR3, IL-5R and FcεR1.

43. (Previously Presented) The bi-specific antibody of claim 42, wherein a binding of said antibody to said cell inhibits allergic-type reactions.

44. (Previously Presented) The bi-specific antibody of claim 42, wherein said first and second target recognition components are linked via any one of a cross-linker, a linker compound, a carrier, a synthetic spacer, an immobilizing substrate and a (Gly₄Ser)₃ motif based flexible region.

45. (Previously Presented) The bi-specific antibody of claim 42, wherein said first and second target recognition components are cross-linked.

46. (Cancelled)

47. (Previously Presented) The bi-specific antibody of claim 42, wherein said recognition component is selected from any one of a naturally occurring, synthetic or recombinant antibody, single chain Fv (scFv), bi-functional scFv, diabody, F(ab) unit, F(ab') unit, bi-specific F(ab') conjugate, chemically

In re Application of: Francesca LEVI-SCHAFFER et al
 Serial No.: 10/594,926
 Filed: April 30, 2008
 Office Action Mailing Date: October 1, 2010

Examiner: ROONEY Nora Maureen
 Group Art Unit: 1644
 Attorney Docket: 32379
 Confirmation No.: 5770

cross-linked bi-functional antibody, linear antibody or a F(ab')₂ antigen binding fragment of an antibody.

48. (Previously Presented) The bi-specific antibody of claim 42, wherein said recognition component is a F(ab') unit.

49. (Cancelled)

50. (Previously Presented) A pharmaceutical composition comprising as an active agent the bi-specific antibody of claim 42.

51. (Previously Presented) The pharmaceutical composition of claim 50, further comprising buffers, additives, stabilizers, diluents and/or excipients.

52. (Currently Amended) A method of treating ~~an allergy disease or condition associated with mast cell and/or eosinophil and/or basophil mediated reactions~~, the method comprising administering to a subject in need thereof a therapeutically effective amount of the ~~a~~ bi-specific antibody, ~~wherein said bi-specific antibody comprises:~~

(i) ~~a, first target recognition component which specifically binds to the inhibitory receptor IRp60 or homologues thereof; and~~

(ii) ~~a second target recognition component which specifically binds to a marker specific for a mast cell, an eosinophil and/or a basophil of claim 42,~~ thereby treating the ~~disease or condition associated with mast cell and/or eosinophil and/or basophil mediated reactions~~ allergy.

In re Application of: Francesca LEVI-SCHAFFER et al
 Serial No.: 10/594,926
 Filed: April 30, 2008
 Office Action Mailing Date: October 1, 2010

Examiner: ROONEY Nora Maureen
 Group Art Unit: 1644
 Attorney Docket: 32379
 Confirmation No.: 5770

53. (Currently Amended) The method of claim 51, wherein said ~~disease or condition is selected from the group consisting of:~~allergy comprises an allergic asthma, ~~allergic rhinitis, allergic conjunctivitis, atopic dermatitis and atopic eczema, allergic disorders and responses to various allergens, systemic anaphylaxis, systemic mastocytosis, morphea/urticaria pigmentosa, mast cell leukemia, atherosclerosis, graft rejection, multiple sclerosis, fibrotic lung diseases, neurofibromatosis, keloids, scleroderma, rheumatoid arthritis, osteoarthritis, acute gout, ocular cicatricial pemphigoid, Crohn's disease, peritoneal adhesions, chronic graft versus host disease (GVHD), eosinophil myalgia syndrome, bronchial asthma, nasal polyposis, Wegener's granulomatosis, interstitial and other pulmonary diseases, chronic eosinophilic pneumonia, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, sarcoidosis, idiopathic pulmonary fibrosis, neoplastic and myeloproliferative diseases, T cell lymphomas and Hodgkin's disease.~~

54-55. (Cancelled)